Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 3Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Pancreatic Neoplasms 10Colorectal Neoplasms 5Stomach Neoplasms 3Rhabdomyosarcoma 3Osteosarcoma 3Biliary Tract Neoplasms 3Sarcoma, Ewing 2Recurrence 2Rectal Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Wilms Tumor 1Small Cell Lung Carcinoma 1Small Bowel Adenocarcinoma 1Sarcoma 1Rhabdoid Tumor 1Rectal Cancer Patients 1Peritoneal Neoplasms 1PDAC - Pancreatic Ductal Adenocarcinoma 1Ovarian Neoplasms 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Nasopharyngeal Carcinoma 1Metastatic Gastric Adenocarcinoma 1Metastatic Adenocarcinoma of the Pancreas 1Malignant Ascites 1Hepatoblastoma 1Gastrointestinal Neoplasms 1Gastroesophageal Junction Adenocarcinoma 1Gastro-enteropancreatic neuroendocrine tumor 1

Interventions

Cyclophosphamide 12Specimen Handling 9cabozantinib 8X-Rays 8Magnetic Resonance Spectroscopy 8fludarabine 7Phantoms, Imaging 7Biopsy 7Temozolomide 6Gemcitabine 5regorafenib 4pembrolizumab 4Vincristine 4Nuclear Medicine Department, Hospital 4Nivolumab 4Methotrexate 4Doxorubicin 4olaparib 3irinotecan sucrosofate 3fludarabine phosphate 3dinutuximab 3Zoledronic Acid 3Surveys and Questionnaires 3Irinotecan 3Ifosfamide 3Cisplatin 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Osteosarcoma × irinotecan sucrosofate × 1 year × Clear all
NCT04901702 2026-05-19

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

St. Jude Children's Research Hospital

Phase 1/2 Recruiting
90 enrolled
CNSGastrointestinalGenitourinarySarcoma

Neoplasms, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

NCT07479732 2026-03-18

Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma

Peking University People's Hospital

Phase 1/2 Recruiting
56 enrolled
Sarcoma

Osteosarcoma

NCT07444918 2026-03-03

Liposomal Irinotecan, Vincristine, Temozolomide, and Anlotinib for R/R Pediatric Solid Tumors

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Not yet recruiting
33 enrolled
Sarcoma

Recurrence, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡